MetaCap

Bambusa Therapeutics (BBTX) vs MeiraGTx (MGTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bambusa Therapeutics is the larger company by market cap ($815.1 million vs $779.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBTX+6.74%MGTX-15.91%
+16%-1%-17%
Oct 30, 20261 yearNov 20, 2026
BBTX+6.74%MGTX-15.91%
+9%-4%-17%
Oct 26, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBTX versus MGTX key metrics
MetricBBTXMGTX
Share price$16.00$7.98
Market cap$815.08M$779.89M
1-day change+2.89%-1.97%
YTD return—+0.38%
1-year return—+6.97%
5-year return—-55.54%
P/E ratio (TTM)—9.17
EPS (TTM)$-1.73$0.87
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$81.39M
Revenue growth (YoY)—+144.57%
Net income (latest FY)—$-114.20M
Operating margin—-130.20%
Net margin—-140.31%
52-week high$17.65$15.35
52-week low$13.60$6.62
Distance from 52-week high-9.35%-48.01%
Analyst consensus—strong_buy
Avg. price target upside—+247.74%
Average volume359.41K837.25K
Shares outstanding50.94M97.73M
Employees26386
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Bambusa Therapeutics

BBTX stock →

Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 26 employees

About MeiraGTx

MGTX stock →

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 386 employees

BBTX vs MGTX FAQ

Which is bigger, Bambusa Therapeutics or MeiraGTx?

Bambusa Therapeutics (BBTX) is larger, with a market capitalization of $815.08M compared with $779.89M for MeiraGTx (MGTX).

Are Bambusa Therapeutics and MeiraGTx in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons